Auswirkungen von Atorvastatin auf menschliches Sperma und Gonadenhormone
Auswirkungen einer durch ein Statin induzierten Senkung des Cholesterinspiegels auf die Spermienqualität
Recently, concerns about the effect of atorvastatin intake on men fertility have been raised. However, this statin has never been investigated regarding its influence on male fertility, notably sperm quality.
The aim of this pilot study is to evaluate the efficacy and the safety of a decrease of cholesterol blood levels, induced by taking atorvastatin, on sperm quality of normocholesterolaemic and healthy men without confounding factors.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Detaillierte Beschreibung
The main objective is to estimate the safety of atorvastatin on fertility of normocholesterolaemic and healthy men (having normal blood lipid profile and normal sperm parameters) by analyzing its effects on sperm parameters: ejaculate volume, sperm count, total and progressive motility, percentage of typical forms.
The secondary objectives are to assess the changes in:
- hormonal profile: gonadotropins and testosterone plasma levels
- lipid composition of sperm and seminal fluid;
- spermatozoa capacitation markers
- accessory glands markers.
The efficacy is estimated by measuring the lipid lowering action of atorvastatin. It is expected a decrease by 20 and 40% of total cholesterol blood and LDL-cholesterol levels, respectively (total cholesterol <1.5 g / l and LDL-cholesterol <1g / l).
Considering this protocol as a pilot study to evaluate safety and efficacy, sample size estimation was fixed considering a Fleming design at one stage. These designs with one group and multi-stages (between 1 and 5) can be seen as filtering steps leading to the decision type go/no go. With a type I error a and statistical power (1-β) equals respectively 5% and 90%, n=17 subjects were necessary to reject the hypotheses of minimal (p=0.85) and maximal (p=0.95) acceptable non-toxicity. If 1 subject or more presented a toxicity, the treatment was considered no safe. To measure the evolution of total cholesterol and LDL-cholesterol levels concerning the efficacy, n=17 subjects were necessary to show a minimal paired difference (to be detected) of 0.5 with expected standard-deviation of difference = 0.5, correlation coefficient of 0.5, a= 5% (two-sided) for a power greater than 90% (1-β=97%).
Subjects are included after a screening visit (visit 0), during which routine laboratory biochemical tests are performed, an electrocardiogram is taken, blood pressure, weight and height are measured; physical examination including testis evaluation and semen parameters are analyzed according to WHO standards 1999 .
The subjects take atorvastatin orally (10mg/day (d), Tahor©, Pfizer Laboratory) during 5 months allowing to study atorvastatin effects on human spermatogenesis and epididymal maturation (one cycle requiring approximately 3 months).
Blood and semen parameters were measured :
- before to take atorvastatin treatment (visit 1)
- at the end of the therapy (visit 3)
- and 3 months after the end of treatment, (visit 4) to perform measurements during different cycles of spermatogenesis on a same subject. After two months of treatment, a consultation (visit 2) is realized to ensure good tolerance to treatment and to control treatment efficiency.
Biochemical clinical and semen measurements take before treatment were considered as "control baseline measures".
Studientyp
Studientyp
Einschreibung (Tatsächlich)
Einschreibung
Phase
Phase
- Phase 1
Kontakte und Standorte
Studienorte
-
-
-
Clermont-Ferrand, Frankreich, 63003
- CHU de Clermont-Ferrand
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Men :
- between 18 and 65 years ;
- with normal conventional semen parameters and negative semen culture according to WHO standards 1999 : volume ejaculate ≥ 2 ml, sperm count ≥ 20millions/ml, total motility ≥ 50% progressive motility ≥ 30%, typical forms ≥ 20%;
- with normal blood lipid profile: total cholesterol < 2.50g/L, triglycerides < 1.70g/L, HDL-C > 0.35 g/L and LDL-C < 2.2 g/L;
- without known pathology or ongoing treatment
Exclusion Criteria:
- Subjects with medical or surgical history that may make them at risk during the study,
- Subjects with cons-indications to taking atorvastatin
- Subjects with an active liver disease or increased level of serum transaminases
- Subjects with a history of allergy
- Subjects whose lipid parameters do not match the inclusions criteria or receiving lipid-lowering therapy
- Subject with abnormal semen analysis or cryptorchidism or a varicocele
- Subjects who participated in another clinical trial or other experimentation or other tolerance study of a drug
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Nicht randomisiert
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: Atovastatin
|
The aim of this pilot study is to evaluate the efficacy and the safety of a decrease of cholesterol blood levels, induced by taking atorvastatin, on sperm quality of normocholesterolaemic and healthy men without confounding factors.
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
Beobachtungen aller Veränderungen der Samenqualität nach 5 Monaten Behandlung mit Atorvastatin
Zeitfenster: im Monat 5
|
im Monat 5
|
|
Beobachtungen aller Veränderungen der Samenqualität nach 5 Monaten Behandlung mit Atorvastatin und nach 3 Monaten nach dessen Absetzen
Zeitfenster: im Monat 8
|
im Monat 8
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
hormonal profile: gonadotropins and total testosterone plasma levels
Zeitfenster: at month 5
|
All modifications observed after 5 months of atorvastatin therapy and after 3 months after the end of treatment on |
at month 5
|
|
lipid composition of sperm and seminal fluid
Zeitfenster: at month 5
|
All modifications observed after 5 months of atorvastatin therapy and after 3 months after the end of treatment on |
at month 5
|
|
spermatozoa capacitation markers
Zeitfenster: at month 5
|
All modifications observed after 5 months of atorvastatin therapy and after 3 months after the end of treatment on |
at month 5
|
|
accessory glands markers
Zeitfenster: at month 5
|
All modifications observed after 5 months of atorvastatin therapy and after 3 months after the end of treatment on |
at month 5
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Mitarbeiter
Mitarbeiter
Ermittler
Ermittler
- Hauptermittler: Igor TAUVERON, University Hospital, Clermont-Ferrand
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Studienbeginn
Primärer Abschluss (Tatsächlich)
Primärer Abschluss
Studienabschluss (Tatsächlich)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Geschätzt)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Molekulare Mechanismen der pharmakologischen Wirkung
- Antimetaboliten
- Hypolipidämische Mittel
- Lipidregulierende Mittel
- Heterocyclische Verbindungen, 1-Ring
- Heterocyclische Verbindungen
- Fettsäuren
- Lipide
- Azolen
- Pharmakologische Maßnahmen
- Chemische Handlungen und Verwendung
- Therapeutische Anwendungen
- Pyrrolen
- Heptansäuren
- Atorvastatin
- Anticholesteremic Agents
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- CHU-0185
- 2006-004376-12
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .